Clinical trials · Texas
Tumor clinical trials in Texas
We’re tracking 578 recruiting tumor studies with a site in Texas — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Webster, TexasAges 18 years+ - NCT05342454Recruiting
Brain tumor surgery patients using brain scan and mapping software
This study checks a new computer software tool that helps doctors map important brain networks and how blood flow responds during brain scans. It may help improve planning and safety for people having brain tumor surgery.
Houston, TexasAges 18 years+ - NCT05319015RecruitingPhase 2
Combination drug therapy before surgery for kidney cancer with vena cava clot
This trial tests two drugs, lenvatinib and pembrolizumab, given before surgery to shrink kidney cancer that has spread into the large vein carrying blood to the heart (the vena cava). The goal is to see if this approach makes surgery more effective and improves outcomes.
Dallas, TexasAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Austin, TexasAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Dallas, TexasAges 18 years+ - NCT05195710RecruitingPhase 1
Pre-surgery Y-90 treatment to grow future liver volume
This trial tests a radiation treatment called Y-90 given before liver surgery for colorectal cancer that has spread to the liver. The goal is to help the liver grow enough for safer, curative surgery, either right away or as part of a two-step operation.
Houston, TexasAges 18 years+ - NCT05111561RecruitingPhase 1
Testing a two-drug combo for RAS-mutant or triple negative breast cancer
This study tests a combination of two new drugs, ZEN003694 and binimetinib, for people with advanced solid tumors that have certain gene changes (like RAS mutations) or triple negative breast cancer. The goal is to see if this combination can shrink tumors or slow their growth.
Galveston, TexasAges 18 years+ - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Tyler, TexasAges 18 years+ - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Houston, TexasAges 18 years+ - NCT05134142Recruiting
Quality of life after hemipelvectomy for pelvic tumors
This study looks at how people with pelvic tumors feel and function after a hemipelvectomy (surgery removing part of the hip/pelvis). It aims to better understand recovery and day-to-day quality of life after this operation.
Houston, TexasAges Any age - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Austin, TexasAges 18 years+ - NCT05053555Recruiting
High-dose radiation treatment for hard-to-remove liver tumors
This study uses a form of targeted radiation placed inside/near the liver to treat liver tumors that can’t be surgically removed. It’s meant to shrink or control tumors, especially when they sit near blood vessels or other sensitive organs.
Houston, TexasAges 19 years+ - NCT05049538Recruiting
Liquid blood tests to predict endometrial cancer return
This trial studies whether blood “liquid biopsies” and tumor genetic testing can help predict whether endometrial cancer will come back after treatment. Results may help doctors plan follow-up and additional care based on a person’s recurrence risk.
Houston, TexasAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05059678Recruiting
Parenting support for families facing advanced cancer
This study tests a program to help parents with advanced cancer support their children and manage family life during treatment. It may help you feel more confident as a parent while coping with cancer.
Houston, TexasAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Study of two new drugs for advanced kidney, prostate, lung, or mesothelioma cancer
This study tests two new study drugs (TT-4 and TT-10) alone and together in people with certain advanced cancers that have not responded to standard treatments. The goal is to see if these drugs are safe and effective in shrinking tumors or slowing the cancer's growth.
Houston, TexasAges 18 years+ - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Edinburg, TexasAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Houston, TexasAges 18 years+ - NCT04906434RecruitingPhase 1
Study of ABSK-011 for advanced solid tumors
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Houston, TexasAges 18–75 - NCT04879121RecruitingPhase 2
Larotrectinib for tumors with extra NTRK gene copies
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
Houston, TexasAges 16 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT04723095Recruiting
Cervical neuroendocrine cancer registry for past and present patients
This study builds a registry (a secure database) of people who have had cervical neuroendocrine cancer, including small cell or large cell types. It helps researchers learn more about these cancers and may improve future care and research planning.
Houston, TexasAges Any age
Tumor trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting tumor studies listed above.
- The University of Texas MD Anderson Cancer Center · 17 studies
- University of Texas Southwestern Medical Center · 2 studies
- Dallas VA Medical Center
- Houston Methodist Hospital
- NEXT Oncology /ID# 243007
- NEXT Oncology Austin /ID# 243005
- Next Oncology Dallas /ID# 276254
- NEXT Virginia, LLC
What taking part in a tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there tumor clinical trials in Texas?
- Yes. We're currently tracking 578 recruiting tumor studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a tumor study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New tumor studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.